MedTrace Logo

Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)

NCT02550717 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 398158

Last updated 2018-10-24

No results posted yet for this study

Summary

To investigate the risk of major bleeding (including gastrointestinal and intracranial bleeding episodes) among new users of low-dose acetylsalicylic acid (ASA) in clinical practice

Conditions

Interventions

DRUG

Acetylsalicylic Acid (Aspirin, BAYE4465)

Low-dose ASA for secondary prevention of cardiovascular events

DRUG

Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs

Secondary prevention of cardiovascular events

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
40 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • United Kingdom

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02550717 on ClinicalTrials.gov